Cancilico is a healthcare technology company at the forefront of integrating artificial intelligence into image-based diagnostics. The company specializes in developing AI-driven software solutions for hematological diagnostics, with its flagship product MyeloAID automating the morphological analysis of bone marrow smears. By leveraging proprietary datasets from leading European hematology centers and expert-labeled data, Cancilico delivers rapid, accurate, and reproducible myelograms in minutes. The company also offers custom AI services to pharmaceutical firms and research institutions, supporting drug development, disease subtype identification, and medical research. Cancilico’s mission is to enhance diagnostic accuracy, reduce workload for clinicians, and advance patient outcomes through innovative AI technology.